The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial.


Journal

European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373

Informations de publication

Date de publication:
02 2019
Historique:
received: 29 08 2018
revised: 24 11 2018
accepted: 09 12 2018
pubmed: 17 1 2019
medline: 10 5 2020
entrez: 17 1 2019
Statut: ppublish

Résumé

Sunitinib is administered on a rigid schedule that may not be optimal for all patients. We hypothesised that toxicity-driven dose and schedule changes would optimise drug exposure and outcome for each patient. In a phase 2 trial, 117 patients with metastatic clear cell renal cell cancer were started on sunitinib 50 mg/day with the aim to treat for 28 days. Treatment breaks were reduced to 7 days. Sunitinib dose and the number of days on therapy were individualised based on toxicity aiming for ≤ grade II toxicity with dose escalation in patients with minimal toxicity. The null hypothesis for the primary end-point was a progression-free survival (PFS) of 8.5 months based on a study with similar eligibility criteria. The null hypothesis was rejected (p < 0.001) with a median PFS of 12.5 months (95% confidence interval [CI]: 9.6-16.5). The median overall survival was 38.5 months (95% CI: 28.3-not reached). The objective response rate (46.1%) and stable disease rate (38.5%) translated into a clinical benefit for 84.6% of patients with no decline in quality of life scores during therapy. Fewer patients were dose reduced (26.5% vs. 50%) or discontinued due to toxicity (7.7 vs. 18-20%) compared to standard sunitinib dosing, and 20 (18.4%) patients were dose escalated to 62.5 mg (12) and 75 mg (8) with a wide individual variation in the optimal dose and treatment duration. Individualised sunitinib therapy is feasible, safe and an effective method to manage toxicity with one of the best efficacy seen for oral vascular endothelial growth factor inhibitors in metastatic renal cell carcinoma. CLINICALTRIALS. NCT01499121.

Sections du résumé

BACKGROUND
Sunitinib is administered on a rigid schedule that may not be optimal for all patients. We hypothesised that toxicity-driven dose and schedule changes would optimise drug exposure and outcome for each patient.
MATERIALS AND METHODS
In a phase 2 trial, 117 patients with metastatic clear cell renal cell cancer were started on sunitinib 50 mg/day with the aim to treat for 28 days. Treatment breaks were reduced to 7 days. Sunitinib dose and the number of days on therapy were individualised based on toxicity aiming for ≤ grade II toxicity with dose escalation in patients with minimal toxicity. The null hypothesis for the primary end-point was a progression-free survival (PFS) of 8.5 months based on a study with similar eligibility criteria.
RESULTS
The null hypothesis was rejected (p < 0.001) with a median PFS of 12.5 months (95% confidence interval [CI]: 9.6-16.5). The median overall survival was 38.5 months (95% CI: 28.3-not reached). The objective response rate (46.1%) and stable disease rate (38.5%) translated into a clinical benefit for 84.6% of patients with no decline in quality of life scores during therapy. Fewer patients were dose reduced (26.5% vs. 50%) or discontinued due to toxicity (7.7 vs. 18-20%) compared to standard sunitinib dosing, and 20 (18.4%) patients were dose escalated to 62.5 mg (12) and 75 mg (8) with a wide individual variation in the optimal dose and treatment duration.
CONCLUSIONS
Individualised sunitinib therapy is feasible, safe and an effective method to manage toxicity with one of the best efficacy seen for oral vascular endothelial growth factor inhibitors in metastatic renal cell carcinoma. CLINICALTRIALS.
GOV IDENTIFIER
NCT01499121.

Identifiants

pubmed: 30648632
pii: S0959-8049(18)31552-1
doi: 10.1016/j.ejca.2018.12.006
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Sunitinib V99T50803M

Banques de données

ClinicalTrials.gov
['NCT01499121']

Types de publication

Clinical Trial, Phase II Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

69-77

Informations de copyright

Copyright © 2018 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Auteurs

Georg A Bjarnason (GA)

Sunnybrook Odette Cancer Centre, 2075 Bayview Ave, Toronto, Ontario, M4N 3M5, Canada. Electronic address: georg.bjarnason@sunnybrook.ca.

Jennifer J Knox (JJ)

Princess Margaret Cancer Centre, 610 University Avenue, Toronto, Ontario, M5G 2M9, Canada.

Christian K Kollmannsberger (CK)

BC Cancer Agency, Vancouver Cancer Centre, Vancouver, British Columbia, V5Z 4E6, Canada.

Denis Soulieres (D)

Centre Hospitalier de L'Universite de Montreal, 1560 Sherbrooke Est, Montreal, Québec, H2L 4M1, Canada.

D Scott Ernst (DS)

London Health Sciences Centre, 790 Commissioners Rd East, London, Ontario, N6A 4L6, Canada.

Pawel Zalewski (P)

R.S. McLaughlin Durham Regional Cancer Centre, 1 Hospital Court, Oshawa, Ontario, L1G 2B9.

Christina M Canil (CM)

The Ottawa Hospital Cancer Centre, 501 Smyth Road, Ontario, K1H 8L6, Canada.

Eric Winquist (E)

London Health Sciences Centre, 790 Commissioners Rd East, London, Ontario, N6A 4L6, Canada.

Sebastien J Hotte (SJ)

Juravinski Cancer Centre, 699 Concession Street, Hamilton, Ontario, L8V 5C2, Canada.

Scott A North (SA)

Cross Cancer Institute, 11560 University Avenue, Edmonton, Alberta, T6G 1Z2, Canada.

Daniel Yick Chin Heng (DYC)

Tom Baker Cancer Center, 1331, 29th Avenue NW, Calgary, Alberta, Canada.

Robyn Jane Macfarlane (RJ)

Queen Elizabeth II Health Sciences Centre, 1276 South Park Street, Halifax, Nova Scotia, B3H 2Y9 Canada.

Peter M Venner (PM)

Cross Cancer Institute, 11560 University Avenue, Edmonton, Alberta, T6G 1Z2, Canada.

Anil Kapoor (A)

Juravinski Cancer Centre, 699 Concession Street, Hamilton, Ontario, L8V 5C2, Canada.

Aaron R Hansen (AR)

Princess Margaret Cancer Centre, 610 University Avenue, Toronto, Ontario, M5G 2M9, Canada.

Bernhard J Eigl (BJ)

BC Cancer Agency, Vancouver Cancer Centre, Vancouver, British Columbia, V5Z 4E6, Canada.

Piotr Czaykowski (P)

Cancer Care Manitoba, 675 McDermot Avenue, Winnipeg, Manitoba, R3E 0V9, Canada.

Ben Boyd (B)

Ozmosis Research Inc, 65 Queen St W, Toronto, Ontario, M5H 2M5, Canada.

Lisa Wang (L)

Princess Margaret Cancer Centre, 610 University Avenue, Toronto, Ontario, M5G 2M9, Canada.

Naveen S Basappa (NS)

Cross Cancer Institute, 11560 University Avenue, Edmonton, Alberta, T6G 1Z2, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH